Evidence map›Paper›PMID 19838738›Full record

Trial reportPediatric nephrology (Berlin, Germany)2010

Middle-term use of Cinacalcet in paediatric dialysis patients.

Caroline Platt, Carol Inward, Mary McGraw, Jan Dudley, Jane Tizard, Christine Burren, Moin A Saleem

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479088 (Twelve-month, Multicenter, Intra-subject Controlled), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01479088 phase2 / phase3unknown statusnot on this map

Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.

TypeinterventionalSponsorENRICO VERRINARan2010 to 2013Enrolled30ConditionsSecondary HyperparathyroidismArmsCinacalcet HCl
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Hypercalcemia: a consultant's approach.Pediatric nephrology (Berlin, Germany) · 2018
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cinacalcet administration by gastrostomy tube in a child receiving peritoneal dialysis.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2014
    Article
  16. Cinacalcet monotherapy in neonatal severe hyperparathyroidism: a case study and review.The Journal of clinical endocrinology and metabolism · 2014
    Review
  17. Review
  18. Review
  19. Article
  20. Hypercalcemia in children and adolescents.Current opinion in pediatrics · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Caroline PlattChildren's Renal Unit, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol BS2 8BJ, UK. cazardron@doctors.org.uk
Carol Inward
Mary McGraw
Jan Dudley
Jane Tizard
Christine Burren
Moin A Saleem
Bristol Royal Hospital for Children · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of the calcimimetic drug Cinacalcet were assessed in six children with uncontrolled hyperparathyroidism secondary to stage 5 chronic kidney disease (CKD). Data were collected retrospectively regarding bone biochemistry and medications. Patients were between the ages of 11 months and 14 years on commencing Cinacalcet at initial doses of 0.4-1.4 mg/kg. Treatment, which was well tolerated in the majority and still on going in five patients, was for periods ranging between 3 months and 3 years. All six cases saw at least an 86% reduction in serum parathyroid hormone (PTH). Hypophosphataemia and/or hypocalcaemia were observed in three cases. Overall, achievement of UK Renal Association targets for corrected calcium (Ca), phosphate (P) and the calcium x phosphate product (Ca x P) were unaffected. We conclude that Cinacalcet is an effective treatment for correcting and sustaining correction of uncontrollable PTH levels seen in a difficult group of patients. Importantly, it has allowed the avoidance of parathyroidectomy for a significant time period in all cases. There remain questions about the effect of Cinacalcet on linear growth amongst paediatric dialysis patients, and future studies should aim to address this.

Indexed as

AdolescentChildChild, PreschoolChronic Kidney Disease-Mineral and Bone DisorderCinacalcetFemaleHumansHyperparathyroidism, SecondaryHypocalcemiaHypophosphatemiaInfantKidney Failure, ChronicMaleNaphthalenesParathyroid HormoneRenal DialysisCinacalcetNaphthalenesParathyroid Hormone

Identifiers

PMID19838738
OpenAlexW2095096892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.